Posted by Michael Wonder on 04 Jul 2018
Two of three US pharma companies receive Independence Day treat from NICE
4 July 2018 - NICE has released its final appraisal determinations for Tesaro, Pfizer and BMS cancer medicines.
Niraparib has been recommended for use within the Cancer Drugs Fund as an option for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to the most recent course of platinum-based chemotherapy in adults under certain conditions.
Crizotinib is recommended for use within the Cancer Drugs Fund as an option for treating ROS1‑positive advanced non-small-cell lung cancer in adults, only if the conditions in the managed access agreement are followed.
Nivolumab is not recommended, within its marketing authorisation, for treating locally advanced unresectable or metastatic urothelial carcinoma in adults who have had platinum-containing therapy.
